WEST Search History



DATE: Friday, April 07, 2006

Hide?	Set Name	<u>Query</u>	Hit Count
	DB=PG	PB; THES=ASSIGNEE; PLUR=YES; OP=ADJ	
	L7	(HPTP or protein adj3 tyrosine phosphatase) same (crystal or x-ray)	44
	DB=US	PT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP	=ADJ
	L6	(HPTP or protein adj3 tyrosine phosphatase) same (crystal or x-ray)	34
	L5	L4 and atomic coordinate	1
	L4	L3 and (crystal or x-ray)	170
	L3	L2 and catalytic domain	329
	L2	HPTP or protein adj3 tyrosine phosphatase	1491
	L1	НРТР	72

END OF SEARCH HISTORY

Hit List

Fwd Refs First Hit Clear Generate Collection Print Blavd Refs Generate OACS **Search Results** - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 6631332 B2

Using default format because multiple data bases are involved.

L5: Entry 1 of 1

File: USPT

Oct 7, 2003

US-PAT-NO: 6631332

DOCUMENT-IDENTIFIER: US 6631332 B2

TITLE: Methods for using functional site descriptors and predicting protein

function

DATE-ISSUED: October 7, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Skolnick; Jeffrey San Diego CA Fetrow; Jacquelyn S. San Diego CA

US-CL-CURRENT: 702/19; 435/4, 436/86, 702/27

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw. De Clear **Cenerate Collection** Print Fwd Refs **Blood** Refs Cenerate OACS Terms Documents and atomic coordinate 1

> **Display Format:** -Change Format

Previous Page Next Page Go to Doc#

Hit List

Generate Collection Fwd Refs Blavd Refs First Hit Clear Print Cenerate OACS

Search Results - Record(s) 1 through 30 of 34 returned.

☐ 1. Document ID: US 7005445 B2

Using default format because multiple data bases are involved.

L6: Entry 1 of 34

File: USPT

Feb 28, 2006

US-PAT-NO: 7005445

DOCUMENT-IDENTIFIER: US 7005445 B2

TITLE: Protein kinase and phosphatase inhibitors and methods for designing them

DATE-ISSUED: February 28, 2006

PRIOR-PUBLICATION:

DOC-ID

DATE

US 20030166615 A1

September 4, 2003

INVENTOR-INFORMATION:

NAME Hangauer, Jr.; David G. CITY

ZIP CODE STATE

ZIP CODE

COUNTRY

El-Araby; Moustafa E.

Amherst

NY

Plainsboro

NJ

US

Milkiewicz; Karen L.

Exton

PA

US

US-CL-CURRENT: 514/419; 548/469

Full Title C	itation Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWAC	Draw, De
					_	·	•			

☐ 2. Document ID: US 6797513 B2

L6: Entry 2 of 34

File: USPT

Sep 28, 2004

US-PAT-NO: 6797513

DOCUMENT-IDENTIFIER: US 6797513 B2

TITLE: Nucleic acid encoding CLK2 protein kinases

DATE-ISSUED: September 28, 2004

INVENTOR-INFORMATION:

NAME CITY STATE

COUNTRY

Ullrich; Axel Nayler; Oliver Munchen Graefehing

DE DE

http://westbrs:9000/bin/gate.exe?f=TOC&state=q9n3m3.8&ref=6&dbname=USPT,USOC,EP... 4/7/06

Record List Display Page 2 of 22

US-CL-CURRENT: 435/325; 435/194, 435/252.3, 435/254.11, 435/320.1, 435/69.1, 530/300, 530/350, 536/23.1, 536/23.5

ABSTRACT:

The present invention relates to nucleic acid molecules encoding mCLK2, mCLK3, and mCLK4 polypeptides, nucleic acid molecules-encoding portions of their amino acid sequences, nucleic acid vectors harboring such nucleic acid molecules, cells containing such nucleic acid vectors, purified polypeptides encoded by such nucleic acid molecules, and antibodies to such polypeptides. Also included are assays that contain at least one CLK protein kinase related molecule. Diagnosis and treatment of an abnormal condition related to RNA splicing or cell proliferation in an organism by using a CLK protein kinase related molecule or compound are disclosed. A method of using a CLK protein kinase related molecule or compound as a contraceptive to reproduction in male organisms is also disclosed.

8 Claims, 7 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 7

Full Title Citation	Front Review Classification	n Date Reference Seguence	s Attachments Claims KMC Draw De
☐ 3. Documer	nt ID: US 6797501 B2		
L6: Entry 3 of 3	4	File: USPT	Sep 28, 2004

US-PAT-NO: 6797501

DOCUMENT-IDENTIFIER: US 6797501 B2

TITLE: Protein tyrosine phosphatase PTP20 and related products and methods

DATE-ISSUED: September 28, 2004

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Aoki; Naohita Nagoya JP Ullrich; Axel Martinsried DE

US-CL-CURRENT: <u>435/194</u>; <u>435/195</u>, <u>435/196</u>, <u>435/252.3</u>, <u>435/320.1</u>, <u>530/300</u>, <u>530/350</u>, <u>536/23.2</u>

ABSTRACT:

The present invention relates to a novel polypeptide, PTP20, and to nucleic acid molecules encoding the polypeptide. The invention also relates to nucleic acid molecules encoding portions of the phosphatase, nucleic acid vectors containing PTP20 related nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such recombinant cells, antibodies to such polypeptides, and methods of identifying compounds that bind PTP20 or abrogate its interactions with natural binding partners. Also disclosed are methods for diagnosing abnormal conditions in an organism with PTP20 related molecules or compounds.

17 Claims, 0 Drawing figures

Record List Display Page 3 of 22

Exemplary Claim Number: 1

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw. De

☐ 4. Document ID: US 6780625 B2

L6: Entry 4 of 34

File: USPT

Aug 24, 2004

US-PAT-NO: 6780625

DOCUMENT-IDENTIFIER: US 6780625 B2

TITLE: Glycogen synthase kinase-3 inhibitors

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Eldar-Finkelman; Hagit Shoham IL

US-CL-CURRENT: $\frac{435}{194}$; $\frac{435}{15}$, $\frac{514}{7}$, $\frac{530}{324}$, $\frac{530}{325}$, $\frac{530}{326}$, $\frac{530}{327}$, $\frac{530}{328}$,

530/329

ABSTRACT:

Peptide inhibitors of glycogen synthase kinase-3 (GSK-3) have an amino acid sequence motif of XZXXXS(p)X, wherein S(p)=phosphorylated serine or phosphorylated threonine, X=any amino acid, and Z=any amino acid except serine or threonine. These inhibitors, which are about 7 to 50 amino acids long, are specific for GSK-3 and strongly inhibit the enzyme with an IC.sub.50 of about 150 .mu.M. Also provided are methods of treating biological conditions mediated by GSK-3 activity, such as potentiating insulin signaling in a subject, treating or preventing type 2 diabetes in a patient, and treating Alzheimer's Disease by administering peptide inhibitors. Compositions of these peptide inhibitors and pharmaceutically acceptable carriers are also provided, as is a method for identifying inhibitors of GSK-3. The invention further relates to a computer-assisted method of structure based drug design of GSK-3 inhibitors using a three-dimensional structure of a peptide substrate of GSK-3.

13 Claims, 11 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw, De

□ 5. Document ID: US 6692916 B2

L6: Entry 5 of 34

File: USPT

Feb 17, 2004

US-PAT-NO: 6692916

DOCUMENT-IDENTIFIER: US 6692916 B2

** See image for Certificate of Correction **

Record List Display Page 4 of 22

TITLE: Systems and methods for characterizing a biological condition or agent using precision gene expression profiles

DATE-ISSUED: February 17, 2004

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Bevilacqua; Michael P. Boulder CO
Bankaitis-Davis; Danute M. Longmont CO
Cheronis; John C. Conifer CO
Tryon; Victor Loveland CO

US-CL-CURRENT: 435/6; 702/19, 702/20

ABSTRACT:

Methods are provided for evaluating a biological condition of a subject using a calibrated profile data set derived from a data set having a plurality of members, each member being a quantitative measure of the amount of a subject's RNA or protein as distinct constituents in a panel of constituents. The biological condition may be a naturally occurring physiological state or may be responsive to treatment of the subject with one or more agents. Calibrated profile data sets may be used as a descriptive record for an agent.

17 Claims, 59 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 49

Full Title	Citation Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWAC	Draw, De

☐ 6. Document ID: US 6673908 B1

L6: Entry 6 of 34 File: USPT Jan 6, 2004

US-PAT-NO: 6673908

DOCUMENT-IDENTIFIER: US 6673908 B1

TITLE: Tumor necrosis factor receptor 2

DATE-ISSUED: January 6, 2004

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Stanton, Jr.; Vincent P. Belmont MA

US-CL-CURRENT: <u>536/22.1</u>; <u>435/6</u>, <u>435/91.1</u>, <u>435/91.2</u>, <u>536/23.1</u>, <u>536/24.3</u>, <u>536/24.31</u>,

<u>536/24.33</u>

ABSTRACT:

The present disclosure describes the use of genetic variance information for genes involved in inflammatory or immunologic disease, disorder, or dysfunction. The

Record List Display Page 5 of 22

variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

10 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation Front Review Classification Date Reference Seguences Attachments Claims KWIC Draw. De

☐ 7. Document ID: US 6664089 B2

L6: Entry 7 of 34

File: USPT

Dec 16, 2003

US-PAT-NO: 6664089

DOCUMENT-IDENTIFIER: US 6664089 B2

TITLE: 38692 and 21117, novel dual specificity phosphatase molecules and uses

therefor

DATE-ISSUED: December 16, 2003

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Meyers; Rachel A.

Newton

MΔ

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/71.1, 536/23.2

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 38692 or 21117 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38692 or 21117 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 38692 or 21117 gene has been introduced or disrupted. The invention still further provides isolated 38692 or 21117 proteins, fusion proteins, antigenic peptides and anti-38692 or 21117 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

6 Claims, 19 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference	Seguences	Attachments	Claims	KWC	Draw, De

□ 8. Document ID: US 6632934 B1

L6: Entry 8 of 34

File: USPT

Oct 14, 2003

US-PAT-NO: 6632934

DOCUMENT-IDENTIFIER: US 6632934 B1

Page 6 of 22 Record List Display

TITLE: MORC gene compositions and methods of use

DATE-ISSUED: October 14, 2003

INVENTOR - INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Moreadith; Randall W.	Chapel Hill	NC			
Zinn; Andrew R.	Dallas	TX			
Watson; Mark L.	Dallas	TX			
Inoue; Norimitsu	Yao				JP
Hess; Karl D.	McDade	TX			
Albright; George M.	Irving	TX			

US-CL-CURRENT: 536/23.1

ABSTRACT:

Disclosed are compositions and methods comprising a novel mammalian gene, designated MORC, that is expressed in male germ cells. Also disclosed are polynucleotide compositions comprising a MORC gene from human and murine sources, and polypeptides encoded by these nucleic acid sequences. Methods for preparing MORC polypeptides, transformed host cells, and antibodies reactive with MORC polypeptides are also provided. In certain embodiments, the invention describes methods for diagnosing and treating infertility or testicular cancer, as well as methods for identifying MORC-related polynucleotide and polypeptide compositions.

2 Claims, 27 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 8

Full Title Citation Front Review Classificat	ion Date Reference Sequences :	A ttachments Claims KWMC Draw.De
☐ 9. Document ID: US 6627735 B	32	
L6: Entry 9 of 34	File: USPT	Sep 30, 2003

US-PAT-NO: 6627735

DOCUMENT-IDENTIFIER: US 6627735 B2

TITLE: Islet cell antigen 1851

DATE-ISSUED: September 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Kindsvogel; Wayne	Seattle	WA			
Jelinek; Laura J.	Seattle	WA			
Sheppard; Paul O.	Redmond	WA			
Hagopian; William A.	Seattle	WA			
LaGasse; James M.	Seattle	WA			

US-CL-CURRENT: 530/350; 424/185.1

ABSTRACT:

A mammalian islet cell antigen polypeptide involved in the development of insulindependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.

3 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation	Front Review	Classification Dat	te Reference	Sequences	Attachments	Claims	KWIC	Drawi De
□ 10. Docum		541615 B1				_	_	
L6: Entry 10 of	34		File:	USPT		Apr	1,	2003
US-PAT-NO: 6541615 DOCUMENT-IDENTIFIE	R: US 65416	15 B1						

TITLE: SIRP proteins and uses thereof

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Ullrich; Axel Munchen DE

Kharitonenkov; Alexei Carmel IN

Chen; Zhengiun Graefelfing DE

US-CL-CURRENT: 536/23.1; 435/320.1, 435/325, 435/455, 435/6, 435/7.1, 530/300, 530/350, 536/23.6, 800/8

ABSTRACT:

The present invention features isolated, purified, or enriched nucleic acid encoding a SIRP polypeptide and isolated, purified, or enriched SIRP polypeptide and uses thereof.

17 Claims, 3 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

Full Title Citation	Front Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw, De

☐ 11. Document ID: US 6500937 B1

Page 8 of 22 Record List Display

L6: Entry 11 of 34

File: USPT

STATE

ZIP CODE

Dec 31, 2002

COUNTRY

US-PAT-NO: 6500937

DOCUMENT-IDENTIFIER: US 6500937 B1

TITLE: Nucleotide sequence encoding a mammary cell growth inhibitor

DATE-ISSUED: December 31, 2002

INVENTOR-INFORMATION:

NAME CITY

Ervin, Jr.; Paul R. Ann Arbor МT

US-CL-CURRENT: <u>536/23.1</u>; <u>435/320.1</u>, <u>436/64</u>

ABSTRACT:

A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin.

3 Claims, 21 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 18

-												
Fuli	THE	C History I	Era e é	Daviere.	Class Structure	Fr 4 -	Datass	Campagana	O blanch and a maker		10010	
3 F U.H	1111 E	CRACOIL	rione	Wenlead	Classification	U312	Reference	CONTRACTOR CONTRACTOR	Attachments	LIBIMSI	KMIC	Diratos De
							·	<u> </u>		بحصو		,

☐ 12. Document ID: US 6482605 B1

L6: Entry 12 of 34

File: USPT

Nov 19, 2002

US-PAT-NO: 6482605

DOCUMENT-IDENTIFIER: US 6482605 B1

** See image for Certificate of Correction **

TITLE: Protein tyrosine phosphatase PTP20 and related products and methods

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Aoki; Naohito Nagoya JP Ullrich; Axel Martimiried DE

US-CL-CURRENT: 435/21; 435/194, 435/252.3, 435/320.1, 530/350, 536/23.2

ABSTRACT:

Record List Display Page 9 of 22

The present invention relates to a novel polypeptide, PTP20, and to nucleic acid molecules encoding the polypeptide. The invention also relates to nucleic acid molecules encoding portions of the phosphatase, nucleic acid vectors containing PTP20 related nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such recombinant cells, antibodies to such polypeptides, and methods of identifying compounds that bind PTP20 or abrogate its interactions with natural binding partners. Also disclosed are methods for diagnosing abnormal conditions in an organism with PTP20 related molecules or compounds.

11 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation Front Review Classification D	ate Reference Seguences	Attachments Claims RMC Draw Do
☐ 13. Document ID: US 6455026 B1		
L6: Entry 13 of 34	File: USPT	Sep 24, 2002

US-PAT-NO: 6455026

DOCUMENT-IDENTIFIER: US 6455026 B1

TITLE: Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors

DATE-ISSUED: September 24, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Mueller; Sabine San Francisco CA
Melcher; Thorsten San Francisco CA
Chin; Daniel J. Foster City CA

US-CL-CURRENT: 424/1.49; 424/1.11, 424/1.65, 424/9.1, 435/21

ABSTRACT:

The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents that specifically bind to human protein tyrosine phosphatase-zeta (PTP.zeta.) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.

63 Claims, 1 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference Sequences	Attachments	Claims	KWIC	Drawt De

Record List Display Page 10 of 22

☐ 14. Document ID: US 6451765 B1

L6: Entry 14 of 34

File: USPT

Sep 17, 2002

US-PAT-NO: 6451765

DOCUMENT-IDENTIFIER: US 6451765 B1

** See image for Certificate of Correction **

TITLE: Methods for treating breast cancer using Mammastatin

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Ervin, Jr.; Paul R. Ann Arbor ΜI

US-CL-CURRENT: <u>514/21</u>; <u>424/184.1</u>, <u>424/198.1</u>, <u>436/64</u>, <u>514/2</u>, <u>514/7</u>

ABSTRACT:

A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.

18 Claims, 21 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawi De

☐ 15. Document ID: US 6420153 B1

L6: Entry 15 of 34

File: USPT

Jul 16, 2002

US-PAT-NO: 6420153

DOCUMENT-IDENTIFIER: US 6420153 B1

TITLE: 18232, a novel dual specificity phosphatase and uses therefor

DATE-ISSUED: July 16, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Meyers; Rachel A. Newton MA Weich; Nadine Brookline MA

Record List Display Page 11 of 22

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/325, 536/23.1, 536/23.2, 536/24.1

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.

15 Claims, 9 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 8

Control	Full Title	Citation Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Dram. De
										····	
	□ 16.	Document II	D: US 6	388076 B1							
	L6: Entry	16 of 34				File: U	SPT		May	14,	2002

US-PAT-NO: 6388076

DOCUMENT-IDENTIFIER: US 6388076 B1

TITLE: Protein tyrosine phosphatase-inhibiting compounds

DATE-ISSUED: May 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Mjalli; Adnan	Econdido	CA			
Sarshar; Sepehr	Cardiff by the Sea	CA			
Cao; Xiaodong	Carlsbad	CA			
Bakir; Farid	San Diego	CA			

US-CL-CURRENT: 544/350

ABSTRACT:

Y--X--C(R').dbd.C(R'')COOR''' (A1)

The present invention relates to novel protein tyrosine phosphatase modulating compounds having the general structure shown in Formula (A1), to methods for their preparation, to compositions comprising the compounds, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation

Record List Display Page 12 of 22

of the activity of molecules with phosphotyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryoic cells, whole animals and human beings. R' and R" are independently selected from the group consisting of hydrogen, halo, cyano, nitro, trihalomethyl, alkyl, arylalkyl. R'" is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, arylalkyl, X is aryl, Y is selected from hydrogen or ##STR1##

wherein (*) indicates a potential point of attachment to X.

16 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation Front Review Classification D.	ate Reference Sequences Attachme	ents Claims KMC Draw. De
☐ 17. Document ID: US 6372744 B1		
L6: Entry 17 of 34	File: USPT	Apr 16, 2002

US-PAT-NO: 6372744

DOCUMENT-IDENTIFIER: US 6372744 B1

** See image for Certificate of Correction **

TITLE: .beta.-sheet mimetics and methods relating to the use thereof

DATE-ISSUED: April 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Qabar; Maher N.	Redmond	WA		
McMillan; Michael K.	Bellevue	WA	·	
Kahn; Michael S.	Kirkland	WA		
Tulinsky; John E.	Seattle	WA		
Ogbu; Cyprian O.	Bellevue	WA		
Mathew; Jessymol	Bellevue	WA		

US-CL-CURRENT: <u>514/248</u>; <u>514/384</u>, <u>530/323</u>, <u>530/332</u>, <u>548/263.4</u>

ABSTRACT:

.beta.-sheet mimetics and methods relating to the same are disclosed. The .beta.sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and protein-protein binding interactions. Methods of the invention include administration of a .beta.-sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase, transcription factor and/or protein-protein binding interaction.

73 Claims, 7 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 6

Record List Display Page 13 of 22

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw. De

☐ 18. Document ID: US 6300093 B1

L6: Entry 18 of 34

File: USPT

Oct 9, 2001

US-PAT-NO: 6300093

DOCUMENT-IDENTIFIER: US 6300093 B1

TITLE: Islet cell antigen 1851

DATE-ISSUED: October 9, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Kindsvogel; Wayne	Seattle	WA			
Jelinek; Laura J.	Seattle	WA			
Sheppard; Paul O.	Redmond	WA			
Hagopian; William A.	Seattle	WA			
LaGasse; James M.	Seattle	WA			

US-CL-CURRENT: 435/69.1; 435/252.3, 435/252.33, 435/254.11, 435/320.1, 435/325, 530/324, 530/350, 536/23.5

ABSTRACT:

A mammalian islet cell antigen polypeptide involved in the development of insulindependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.

6 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation Front Review Classifica	tion Date Reference Sequences A	itachments Claims KWIC Draw. De
☐ 19. Document ID: US 6238902	B1	
L6: Entry 19 of 34	File: USPT	May 29, 2001

US-PAT-NO: 6238902

DOCUMENT-IDENTIFIER: US 6238902 B1

TITLE: Protein tyrosine phosphatases

DATE-ISSUED: May 29, 2001

Record List Display Page 14 of 22

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Burlingame CA Cheng; Jill Sausalito Lasky; Laurence A. CA

US-CL-CURRENT: 435/196; 435/325, 435/377

ABSTRACT:

This invention concerns new non-receptor protein tyrosine phosphatases of the hematopoietic stem cells (PTP HSC). The invention specifically concerns native murine and human PTP HSCs, their analogs in other mammals, and their functional derivatives. The invention further relates to nucleic acid encoding these proteins, vectors containing and capable of expressing such nucleic acid, and recombinant host cells transformed with such nucleic acid. Assays for identifying agonists and antagonists of the native PTP HSCs, methods for expansion of undifferentiated stem cells, and methods for the induction of stem cell differentiation are also within the scope of the invention.

3 Claims, 15 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 10

Full	Title	Citation Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawi De
 ~^~~											
	20.	Document ID	: US 6	214564 B1							

L6: Entry 20 of 34

File: USPT

Apr 10, 2001

US-PAT-NO: 6214564

DOCUMENT-IDENTIFIER: US 6214564 B1

TITLE: Method of identifying modulators of protein tyrosine phosphatase activity

DATE-ISSUED: April 10, 2001

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Rodan; Gideon A. Bryn Mawr PA Rutledge; Su Jane East Greenville PA Schmidt; Azriel Bryn Mawr PA

US-CL-CURRENT: $\frac{435}{7.1}$; $\frac{435}{252.3}$, $\frac{435}{320.1}$, $\frac{435}{325}$, $\frac{435}{471}$, $\frac{435}{69.1}$, $\frac{435}{7.2}$, 435/70.1, 435/71.1, 435/71.2, 530/350 , 536/23.2

ABSTRACT:

A human protein tyrosine phosphatase (PTP) has been identified and its cDNA has been isolated. This PTP, denoted PTP-OB, has a receptor-like three dimensional structure and is present in osteoblasts. PTP-OB is involved in osteoblast differentiation, and modulators of PTP-OB activity in turn modulate osteoblast differentiation, osteoclast differentiation and osteoclast activity.

Record List Display Page 15 of 22

6 Claims, 12 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 12

Full Title Citation Front Review Classification Date Reference Seguences Attachments Claims KMC Draw De

☐ 21. Document ID: US 6156732 A

L6: Entry 21 of 34

File: USPT

Dec 5, 2000

US-PAT-NO: 6156732

DOCUMENT-IDENTIFIER: US 6156732 A

TITLE: Azole peptidomimetics as thrombin receptor antagonists

DATE-ISSUED: December 5, 2000

INVENTOR-INFORMATION:

NAME CITY

STATE ZIP CODE COUNTRY

Hoekstra; William

Villanova

PA

Hulshizer; Becky L.

North Wales

PA

US-CL-CURRENT: 514/18; 514/17, 514/2, 514/822

ABSTRACT:

Azole derivatives of formula (I): ##STR1## are disclosed as useful in treating platelet-mediated thrombotic disorders.

2 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw. De

☐ 22. Document ID: US 6143879 A

L6: Entry 22 of 34

File: USPT

Nov 7, 2000

US-PAT-NO: 6143879

DOCUMENT-IDENTIFIER: US 6143879 A

** See image for Certificate of Correction **

TITLE: Nucleotide cleaving agents and method

DATE-ISSUED: November 7, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Que, Jr.; Lawrence Roseville MN

Record List Display Page 16 of 22

Hanson; Richard S.

Falcon Heights

MN

Schnaith; Leah M. T.

Redwing

MN

US-CL-CURRENT: 536/23.1; 536/124, 536/24.3, 536/25.3

ABSTRACT:

The present invention provides a unique series of nucleotide cleaving agents and a method for cleaving a nucleotide sequence, whether single-stranded or doublestranded DNA or RNA, using and a cationic metal complex having at least one polydentate ligand to cleave the nucleotide sequence phosphate backbone to yield a hydroxyl end and a phosphate end.

28 Claims, 6 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 5

Full Title Citation Front Review Classificatio	on Date Reference Sequences Atta	a chments Claims KMC Draw De
☐ 23. Document ID: US 6117896 A	1	
L6: Entry 23 of 34	File: USPT	Sep 12, 2000

US-PAT-NO: 6117896

DOCUMENT-IDENTIFIER: US 6117896 A

** See image for Certificate of Correction **

TITLE: Methods for regulating transcription factors

DATE-ISSUED: September 12, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Qabar; Maher N. Redmond WA McMillan; Michael K. Bellevue Kahn; Michael S. Kirkland . WA Tulinsky; John E. Seattle WA Ogbu; Cyprian O. Bellevue WA Mathew; Jessymol Bellevue WA

US-CL-CURRENT: 514/384; 514/248, 530/323, 530/332, 548/263.4

ABSTRACT:

.beta.-sheet mimetics and methods relating to the same are disclosed. The .beta.sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and protein-protein binding interactions. Methods of the invention include administration of a .beta.-sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase, transcription factor and/or protein-protein binding interaction.

Record List Display Page 17 of 22

34 Claims, 7 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 6

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw De

☐ 24. Document ID: US 6074851 A

L6: Entry 24 of 34

File: USPT

Jun 13, 2000

US-PAT-NO: 6074851

DOCUMENT-IDENTIFIER: US 6074851 A

TITLE: Catalytic macro molecules having cdc25B like activity

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Deibel, Jr.; Martin R. Kalamazoo MI
Yem; Anthony W. Kalamazoo MI
Wolfe; Cindy L. Portage MI

US-CL-CURRENT: $\frac{435}{69.7}$; $\frac{435}{194}$

ABSTRACT:

This invention discloses novel forms of catalytic macro molecules that are related to cdc25B, a cell cycle specific phosphatase. These special domains of cdc25B, special fusions with GST, and unique peptides and proteins, their utility, and the method of making them are all described.

3 Claims, 6 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 9

100													
The same of	Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Drawt De
									•				

☐ 25. Document ID: US 6060481 A

L6: Entry 25 of 34

File: USPT

May 9, 2000

US-PAT-NO: 6060481

DOCUMENT-IDENTIFIER: US 6060481 A

TITLE: Method for improving insulin sensitivity using an adenosine receptor

antagonist

DATE-ISSUED: May 9, 2000

Page 18 of 22 Record List Display

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

LaNoue; Kathryn F. Hershey PΑ Harrisburg Crist; George H. PA Linden; Joel M. Charlottesville VA

US-CL-CURRENT: <u>514/263.34</u>; <u>514/263.24</u>

ABSTRACT:

Methods for improving insulin sensitivity in a patient using one or more A.sub.2B adenosine receptor antagonists are disclosed. These methods stimulate insulin dependent glucose uptake in muscle.

15 Claims, 10 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 10

Fuli	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWAC	Drawe De
												<u></u>

☐ 26. Document ID: US 5951979 A

L6: Entry 26 of 34 File: USPT Sep 14, 1999

US-PAT-NO: 5951979

DOCUMENT-IDENTIFIER: US 5951979 A

TITLE: Substrate trapping protein tyrosine phosphatases

DATE-ISSUED: September 14, 1999

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Tonks; Nicholas Huntington NY Flint; Andrew J. Bothell WA

US-CL-CURRENT: 424/94.6; 435/196

ABSTRACT:

Novel protein tyrosine phosphatases in which the invariant aspartate residue is replaced with an alanine residue and which bind to a tyrosine phosphorylated substrate and are catalytically attenuated are described. Also described are methods of identifying tyrosine phosphorylated proteins which complex with the described protein tyrosine phosphatases.

8 Claims, 2 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 6 Record List Display Page 19 of 22

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw De

☐ 27. Document ID: US 5912138 A

L6: Entry 27 of 34

File: USPT

Jun 15, 1999

US-PAT-NO: 5912138

DOCUMENT-IDENTIFIER: US 5912138 A

TITLE: Substrate trapping protein tyrosine phosphatases

DATE-ISSUED: June 15, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Tonks; Nicholas Huntington NY Flint; Andrew J. Bothell WA

US-CL-CURRENT: 435/21; 435/196

ABSTRACT:

Novel protein tyrosine phosphatases in which the invariant aspartate residue is replaced with an alanine residue and which bind to a tyrosine phosphorylated substrate and are catalytically attenuated are described. Also described are methods of identifying tyrosine phosphorylated proteins which complex with the described protein tyrosine phosphatases.

21 Claims, 2 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 6

- 6	***************************************					····		·			<u> </u>		
5	Full	T:45 -	C 24 - 43	F4	Daniel Committee	City and Ministry	D. L.L.	Disk and a second	Elman committee	Attachments		1.0 (4.0 (6.0))	
- 8	F OH		. Lativii	FIORE	Review	LIASSINGATION	uate	reeeence			i i a ime i	KOIMIE:	Draw, De
- 1									كالمستجهدين بمساور		0.0		5.10 5.0

☐ 28. Document ID: US 5866397 A

L6: Entry 28 of 34 File: USPT

Feb 2, 1999

US-PAT-NO: 5866397

DOCUMENT-IDENTIFIER: US 5866397 A

TITLE: Human protein tyrosine phosphatase OB protein

DATE-ISSUED: February 2, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Rodan; Gideon A. Bryn Mawr PA
Rutledge; Su Jane East Greenville PA
Schmidt; Azriel Bryn Mawr PA

Record List Display Page 20 of 22

US-CL-CURRENT: 435/196; 435/69.1, 530/350

ABSTRACT:

A novel human protein tyrosine phosphatase (PTP) has been identified and its cDNA has been isolated. This novel PTP, denoted PTP-OB, has a receptor-like three dimensional structure and is present in osteoblasts. PTP-OB is involved in osteoblast differentiation, and modulators of PTP-OB activity in turn modulate osteoblast differentiation, osteoclast differentiation and osteoclast activity.

7 Claims, 20 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KOMO	Draw, De
							•	······································		· · · · · · · · · · · · · · · · · · ·		

☐ 29. Document ID: US 5770620 A

L6: Entry 29 of 34

File: USPT

Jun 23, 1998

US-PAT-NO: 5770620

DOCUMENT-IDENTIFIER: US 5770620 A

TITLE: Aryl acrylic acid derivatives useful as protein tyrosine phosphatase

inhibitors

DATE-ISSUED: June 23, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Mjalli; Adnan M. M. Vista CA
Cao; Xiaodong Carlsbad CA

Moran; Edmund J. Cardiff CA

US-CL-CURRENT: 514/415; 514/466, 514/471, 514/506, 514/563, 548/495, 549/441,

549/450, 560/42, 562/448

ABSTRACT:

The present invention provides novel protein tyrosine phosphatase modulating compounds having an aryl acrylic acid structure, compositions comprising the compounds, and methods of making and using the same.

27 Claims, 5 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawt De
									,			<u>,</u>

☐ 30. Document ID: US 5688992 A

L6: Entry 30 of 34

File: USPT

Nov 18, 1997

US-PAT-NO: 5688992

DOCUMENT-IDENTIFIER: US 5688992 A

TITLE: O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof

DATE-ISSUED: November 18, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Burke, Jr.; Terrence R.	Bethesda	MD			
Ye; Bin	Gaithersburg	MD			
Akamatsu; Miki	Rockville	MD			
Kole; Hemanta K.	Baltimore	MD			
Yan; Xinjian	Rockville	MD			
Roller; Peter R.	Rockville	MD			

US-CL-CURRENT: <u>560/82</u>; <u>560/76</u>, <u>562/65</u>

ABSTRACT:

The present invention relates to non-phosphorus containing O-malonyltryrosyl compounds, derivatives thereof, uses of the O-malonyltryrosyl compounds in the synthesis of peptides, and O-malonyltryrosyl compound-containing peptides. The Omalonyltyrosyl malonyltyrosyl compounds and O-malonyltryrosyl compound-containing peptides of the present invention are uniquely stable to phosphotases, capable of crossing cell membranes, suitable for application to peptide synthesis of Omalonyltryrosyl compound-containing peptides, and amenable to prodrag defivatization for delivery into cells. The present invention also provides for Omalonyltryrosyl compound-containing peptides which exhibit inhibitory potency against binding interactions of receptor domains with phosphotyrosyl-containing peptide ligands.

11 Claims, 4 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KVVIC	Draw, De
Clear		Gener	169 e 16	lection	Print	F	wd Reis	Bkwd	Refs	Cener	ate ©/	VCS
	<u></u>			 							 1	
	Ter	ms							Dog	cument	s	

Display Format: -Change Format

Previous Page Next Page Go to Doc#

Hit List

First Hit Clear Cenerate Collection Print Fwd Refs Blawd Refs

Generate OACS

Search Results - Record(s) 1 through 30 of 44 returned.

☐ 1. Document ID: US 20060069066 A1

Using default format because multiple data bases are involved.

L7: Entry 1 of 44

File: PGPB

Mar 30, 2006

PGPUB-DOCUMENT-NUMBER: 20060069066

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060069066 A1

TITLE: Glycogen synthase kinase-3 inhibitors

PUBLICATION-DATE: March 30, 2006

INVENTOR - INFORMATION:

NAME CITY STATE COUNTRY

Eldar-Finkelman; Hagit Shoham IL
Portnoy; Moshe Givat Shmuel IL

US-CL-CURRENT: 514/80; 546/22, 548/113

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw, De

☐ 2. Document ID: US 20060046259 A1

L7: Entry 2 of 44 File: PGPB Mar 2, 2006

PGPUB-DOCUMENT-NUMBER: 20060046259

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060046259 A1

TITLE: Differential expression of molecules associated with acute stroke

PUBLICATION-DATE: March 2, 2006

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY Baird; Alison E. Bethesda MD US Moore; David F. Rockville MD US Goldin; Ehud Rockville MD US

US-CL-CURRENT: 435/6; 436/86

Record List Display Page 2 of 15

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw. De

☐ 3. Document ID: US 20060046249 A1

L7: Entry 3 of 44

File: PGPB

Mar 2, 2006

PGPUB-DOCUMENT-NUMBER: 20060046249

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060046249 A1

TITLE: Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways

PUBLICATION-DATE: March 2, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Huang; Fei	Princeton	NJ	US
Fairchild; CraigR	Yardley	PA	US
Lee; FrancisY	Yardley	PA	US
Shaw; Peter	Yardley	PA	US

US-CL-CURRENT: 435/6; 536/24.1

Full	Title	Citation	Front	Review	Classification	Date	Referenc	Sequences	Attachments	Claims	KWAC	Draw, De
 								· · · · · · · · · · · · · · · · · · ·				
	4.]	Docume	nt ID:	US 20	060045853	A 1						
L7: E	ntry	4 of 4	4				File:	PGPB		Mar	2,	2006

PGPUB-DOCUMENT-NUMBER: 20060045853

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060045853 A1

TITLE: Cross-beta structure comprising amyloid-binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity

PUBLICATION-DATE: March 2, 2006

INVENTOR - INFORMATION:

NAME CITY COUNTRY STATE Kroon-Batenburg; Louise Maria Johanna Eemnes NLBouma; Barend NLHouten Kranenburg; Onno Wouter Amsterdam NLGebbink; Martijn Frans Ben Gerard Bunnik NL

US-CL-CURRENT: <u>424/50</u>; <u>424/94.64</u>, <u>435/7.1</u>

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw, De

☐ 5. Document ID: US 20060030544 A1

L7: Entry 5 of 44

File: PGPB

Feb 9, 2006

PGPUB-DOCUMENT-NUMBER: 20060030544

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060030544 A1

TITLE: Protein kinase and phosphatase inhibitors and methods for designing them

PUBLICATION-DATE: February 9, 2006

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY Hangauer; David G. JR. Amherst NY US

El-Araby; Moustafa E. Plainsboro NJ US Milkiewicz; Karen L. Exton PA US

US-CL-CURRENT: 514/80; 514/419, 548/414, 548/493

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KOMC	Draw, De

☐ 6. Document ID: US 20060025361 A1

L7: Entry 6 of 44

File: PGPB

Feb 2, 2006

PGPUB-DOCUMENT-NUMBER: 20060025361

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060025361 A1

TITLE: RNA interference mediated inhibition of protein tyrosine phosphatase-1B

(PTP-1B) gene expression using short interfering nucleic acid (siNA)

PUBLICATION-DATE: February 2, 2006

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

McSwiggen; James Boulder CO US
Beigelman; Leonid Longmont CO US
Usman; Nassim Lafayette CO US

US-CL-CURRENT: 514/44; 536/23.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, Dr
										·		

☐ 7. Document ID: US 20060019913 A1

Record List Display Page 4 of 15

L7: Entry 7 of 44

File: PGPB

Jan 26, 2006

PGPUB-DOCUMENT-NUMBER: 20060019913

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060019913 A1

TITLE: RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)

PUBLICATION-DATE: January 26, 2006

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY McSwiggen; James Boulder CO US Beigelman; Leonid Longmont CO US Usman; Nassim Lafayette CO US

US-CL-CURRENT: <u>514/44</u>; <u>536/23.1</u>

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De

	_	_										

□ 8. Document ID: US 20060014180 A1

L7: Entry 8 of 44

File: PGPB

Jan 19, 2006

PGPUB-DOCUMENT-NUMBER: 20060014180

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060014180 A1

TITLE: Human phosphatase RET31, and variants thereof

PUBLICATION-DATE: January 19, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Jackson; Donald G.	Lawrenceville	NJ	US
Ramanathan; Chandra S.	Wallingford	CT	US
Feder; John N.	Belle Mead	NJ	US
Mintier; Gabe	Hightstown	NJ	US
Lee; Liana	North Brunswick	NJ	US
Nelson; Thomas C.	Lawrenceville	NJ	US
Siemers; Nathan	Pennington	NJ	US
Bol; David	Langhorne	PA	US
Suchard; Suzanne	Wilmington	DE	US
Schieven; Gary	Lawrenceville	NJ	US
Finger; Joshua	San Marcos	CA	US
Todderrud; C. Gordon	Newtown	PA	US
Bassolino; Donna	Hamilton	NJ	US
Krystek; Stanley	Ringoes	NJ	US
Banas; Dana	Hamilton	NJ	US

Record List Display Page 5 of 15

McAtee; Patrick

Pennington

NJ

US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw De

☐ 9. Document ID: US 20060003322 A1

L7: Entry 9 of 44

File: PGPB

Jan 5, 2006

Dec 29, 2005

PGPUB-DOCUMENT-NUMBER: 20060003322

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060003322 A1

TITLE: Bioinformatically detectable group of novel regulatory genes and uses

thereof

PUBLICATION-DATE: January 5, 2006

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

Bentwich; Isaac Kvuzat Shiler IL

US-CL-CURRENT: 435/6

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw Do

File: PGPB

☐ 10. Document ID: US 20050287535 A1

L7: Entry 10 of 44

PGPUB-DOCUMENT-NUMBER: 20050287535 PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050287535 A1

TITLE: Biomarkers for wound healing

PUBLICATION-DATE: December 29, 2005

INVENTOR-INFORMATION:

CITY NAME STATE COUNTRY

McGrath, Kevin P. Alpharetta GΑ US

US-CL-CURRENT: 435/6; 435/7.2

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw De

☐ 11. Document ID: US 20050237522 A1

Record List Display Page 6 of 15

L7: Entry 11 of 44

File: PGPB

Oct 27, 2005

PGPUB-DOCUMENT-NUMBER: 20050237522

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050237522 A1

TITLE: Methods for visualizing crystals and distinguishing crystals from other

matter within a biological sample

PUBLICATION-DATE: October 27, 2005

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

Swift, Kerry M.
Matayoshi, Edmund D.

Libertyville IL US

Richmond IL US

US-CL-CURRENT: <u>356/317</u>; <u>250/461.1</u>

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De
									-			

☐ 12. Document ID: US 20050186630 A1

L7: Entry 12 of 44

File: PGPB

Aug 25, 2005

PGPUB-DOCUMENT-NUMBER: 20050186630

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050186630 A1

TITLE: Extended tethering approach for rapid identification of ligands

PUBLICATION-DATE: August 25, 2005

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY Erlanson, Daniel A. San Francisco CA US Braisted, Andrew C. San Francisco CA US McDowell, Robert San Francisco CA US Prescott, John San Francisco CA US

US-CL-CURRENT: 435/6; 435/7.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De

☐ 13. Document ID: US 20050176101 A1

L7: Entry 13 of 44

File: PGPB

Aug 11, 2005

PGPUB-DOCUMENT-NUMBER: 20050176101

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050176101 A1

Record List Display Page 7 of 15

TITLE: Enzyme expression methods

PUBLICATION-DATE: August 11, 2005

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

West, Brian San Francisco CA US

US-CL-CURRENT: 435/69.1; 435/194, 435/320.1, 435/325, 536/23.2

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw. De

14. Document ID: US 20050147593 A1

L7: Entry 14 of 44 File: PGPB Jul 7, 2005

PGPUB-DOCUMENT-NUMBER: 20050147593

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050147593 A1

TITLE: EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell

disorders

PUBLICATION-DATE: July 7, 2005

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

Kinch, Michael S. Laytonsville MD US

US-CL-CURRENT: 424/93.2; 424/178.1, 424/450, 514/44

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw Do

15. Document ID: US 20050142539 A1

File: PGPB

PGPUB-DOCUMENT-NUMBER: 20050142539

PGPUB-FILING-TYPE: new

L7: Entry 15 of 44

DOCUMENT-IDENTIFIER: US 20050142539 A1

TITLE: Targeted ligands

PUBLICATION-DATE: June 30, 2005

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

Herman, William Thornhill CA

US-CL-CURRENT: 435/5; 435/7.23, 530/388.22, 530/388.3

Jun 30, 2005

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw. De

☐ 16. Document ID: US 20050118164 A1

L7: Entry 16 of 44

File: PGPB

Jun 2, 2005

PGPUB-DOCUMENT-NUMBER: 20050118164

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050118164 A1

TITLE: Targeted ligands

PUBLICATION-DATE: June 2, 2005

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

Herman, William Thornhill CA

US-CL-CURRENT: 424/133.1

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw De

☐ 17. Document ID: US 20050070497 A1

L7: Entry 17 of 44

File: PGPB

Mar 31, 2005

PGPUB-DOCUMENT-NUMBER: 20050070497

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050070497 A1

TITLE: RNA interference mediated inhibtion of tyrosine phosphatase-1B (PTP-1B) gene

expression using short interfering nucleic acid (siNA)

PUBLICATION-DATE: March 31, 2005

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY McSwiggen, James Boulder CO US

Beigelman, Leonid Longmont CO US Usman, Nassim Lafayette CO US

US-CL-CURRENT: <u>514/44</u>; <u>435/375</u>, <u>536/23.1</u>

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw, De

☐ 18. Document ID: US 20050069549 A1

L7: Entry 18 of 44

File: PGPB

Mar 31, 2005

Record List Display Page 9 of 15

PGPUB-DOCUMENT-NUMBER: 20050069549

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050069549 A1

TITLE: Targeted ligands

PUBLICATION-DATE: March 31, 2005

INVENTOR - INFORMATION:

NAME CITY STATE COUNTRY

Herman, William Thornhill CA

US-CL-CURRENT: 424/178.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIČ	Draw, De
 											,	
	19.	Docum	ent ID	: US 2	004022544	8 A1						
L7: E	Entry	19 of	44				File:	PGPB		Nov	11,	2004

PGPUB-DOCUMENT-NUMBER: 20040225448

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040225448 A1

TITLE: Systems and methods for characterizing a biological condition or agent using selected gene expression profiles

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY Bevilacqua, Michael P. Boulder CO US Bankaitis-Davis, Danute M. Longmont CO US Cheronis, John C. Conifer US CO Tryon, Victor Loveland CO US

US-CL-CURRENT: 702/20

	Full	Title	Citation	Front	Review	Classification	Date	Referenc	e Sequences	Attachments	Claims	KWIC	Draw, De
***************************************		·····	······································							·····			
		20.	Docum	ent ID	: US 2	004022544	6 A1						,
	L7:	Entry	20 of	44				File:	PGPB		Nov	11,	2004

PGPUB-DOCUMENT-NUMBER: 20040225446

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040225446 A1

TITLE: Systems and methods for characterizing a biological condition or agent using selected gene expression profiles

Record List Display Page 10 of 15

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

CITY NAME STATE COUNTRY Bevilacqua, Michael P. Boulder CO US Bankaitis-Davis, Danute M. CO Longmont US Cheronis, John C. Conifer CO US Tryon, Victor Loveland US CO

US-CL-CURRENT: 702/19

Full	Title	Citation F	ront	Review	Classification	Date	Referenc	e Sequences	Attachments	Claims	KWIC	Draw, De
 									~~~			
	21.	Documen	t ID:	US 2	004022544	5 A1						
L7:	Entry	21 of 44	<u>l</u>				File:	PGPB		Nov	11,	2004

PGPUB-DOCUMENT-NUMBER: 20040225445

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040225445 A1

TITLE: Systems and methods for characterizing a biological condition or agent using selected gene expression profiles

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY Bevilacqua, Michael P. Boulder CO US Bankaitis-Davis, Danute M. Longmont US CO Cheronis, John C. Conifer CO US Tryon, Victor Loveland US CO

US-CL-CURRENT: 702/19

	Full		Title	Citation	Front	Review	Classification	Date	Referenc	e Sequences	Attachments	Claims	KWIC	Draw, De
											·			
		1	22.	Docum	ent ID	: US 2	004022433	3 A1						
1	: 7:	En	try	22 of	44				File:	PGPB		Nov	11,	2004

PGPUB-DOCUMENT-NUMBER: 20040224333

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040224333 A1

TITLE: Systems and methods for characterizing a biological condition or agent using selected gene expression profiles

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Bevilacqua, Michael P.	Boulder	CO	US
Cheronis, John C.	Conifer	CO	US
Tryon, Victor	Loveland	CO	US
Bankaitis-Davis, Danute M.	Longmont	CO	US

US-CL-CURRENT: 435/6; 702/20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. De
	22	Dogum	ant ID.	110.2	004022432	2 A 1						
1	43.	Docum	בווו זום:	032	004022432	4 AI						
L7: E	Entry	23 of	44				File: P	GPB		Nov	11,	2004

PGPUB-DOCUMENT-NUMBER: 20040224322

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040224322 A1

TITLE: Systems and methods for characterizing a biological condition or agent using selected gene expression profiles

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Bevilacqua, Michael P.	Boulder	CO	US
Bankaitis-Davis, Danute M.	Longmont	CO	US
Cheronis, John C.	Conifer	CO	US
Tryon, Victor	Loveland	CO	US

US-CL-CURRENT: 435/6; 702/20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De
			<del></del>			······································			·····	······		
	24.	Docum	ent ID	: US 2	004021956	8 A1						
L7: E	ntry	24 of	44				File:	PGPB		Nov	4,	2004

PGPUB-DOCUMENT-NUMBER: 20040219568

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040219568 A1

TITLE: Systems and methods for characterizing a biological conditions or agent using selected gene expression profiles

PUBLICATION-DATE: November 4, 2004

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

Bevilacqua, Michael P.	Boulder	CO	US
Cheronis, John C.	Conifer	CO	US
Tryon, Victor	Loveland	CO	US
Bankaitis-Davis, Danute M.	Longmont	CO	US

US-CL-CURRENT: 435/6

A STATE OF THE PARTY OF THE PAR	Full	Title	Citation	Front	Review	Classification	Date	Referen	e Sequences	Attachments	Claims	KWIC	Draw, De
		25.	Docum	ent ID	: US 2	004015722	1 A9						
			25 of					File:	PGPB		Διια	12.	2004
	ш/: г	riict A	25 01	44				riie:	PGPB		Aug	12,	2004

PGPUB-DOCUMENT-NUMBER: 20040157221

PGPUB-FILING-TYPE: corrected

DOCUMENT-IDENTIFIER: US 20040157221 A9

TITLE: Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937,

49931 and 49933 molecules and uses therefor

PUBLICATION-DATE: August 12, 2004

PRIOR-PUBLICATION:

DOC-ID DATE

US 0009501 A1 January 15, 2004

# INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Curtis, Rory A. J.	Ashland	MA	US
Logan, Thomas Joseph	Springfield	PA	US
Glucksmann, Maria Alexandra	Lexington	MA	US
Meyers, Rachel E.	Newton	MA	US
Williamson, Mark J.	Saugus	MA	US
Rudolph-Owen, Laura A.	Medford	MA	US
Chun, Miyoung	Belmont	MA	US
Tsai, Fong-Ying	Newton	MA	US

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

Full Title	Citation Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawi De
□ 26.	Document II	): US 2	004007706	5 A1						
L7: Entry	26 of 44				File:	PGPB		Apr	22,	2004

PGPUB-DOCUMENT-NUMBER: 20040077065

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040077065 A1

Record List Display Page 13 of 15

TITLE: Three dimensional coordinates of HPTPbeta

PUBLICATION-DATE: April 22, 2004

INVENTOR - INFORMATION:

NAME CITY STATE COUNTRY

Evdokimov, Artem Gennady Loveland OH US
Pokross, Matthew Eugene Loveland OH US

US-CL-CURRENT: 435/226; 702/19

Full Title Citation	Front Review	Classification [	Date Reference	Sequences	Attachments	Claims	KMC   Draw De
					_		

File: PGPB

☐ 27. Document ID: US 20040076955 A1

PGPUB-DOCUMENT-NUMBER: 20040076955 PGPUB-FILING-TYPE: new

L7: Entry 27 of 44

DOCUMENT-IDENTIFIER: US 20040076955 A1

TITLE: Methods of diagnosis of bladder cancer, compositions and methods of

screening for modulators of bladder cancer

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

Mack, David H. Menlo Park CA US
Aziz, Natasha Palo Alto CA US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Referenc	e Sequences	Attachments	Claims	KWIC	Drawt De
	28.	Docum	ent ID	: US 2	004001900	1 A1						
L7: I	Entry	28 of	44				File:	PGPB		Jan	29,	2004

PGPUB-DOCUMENT-NUMBER: 20040019001

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040019001 A1

TITLE: RNA interference mediated inhibition of protein typrosine phosphatase-1B

(PTP-1B) gene expression using short interfering RNA

PUBLICATION-DATE: January 29, 2004

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

Apr 22, 2004

Record List Display Page 14 of 15

McSwiggen, James A.

Boulder

CO

US

US-CL-CURRENT: 514/44; 435/375, 536/23.1

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KVMC Draw. De

☐ 29. Document ID: US 20040018513 A1

L7: Entry 29 of 44

File: PGPB

Jan 29, 2004

Jan 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040018513

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040018513 A1

TITLE: Classification and prognosis prediction of acute lymphoblastic leukemia by gene expression profiling

PUBLICATION-DATE: January 29, 2004

INVENTOR - INFORMATION:

NAME CITY STATE COUNTRY Cordova US Downing, James R. TN MS SG Yeoh, Eng-Juh Singapore Wilkins, Dawn E. Oxford US Wong, Limsoon Singapore SG

US-CL-CURRENT: 435/6

ĺ	Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KOAC	Draw. De
												***************************************	
		30.	Docum	ent ID	: US 2	004000950	1 A1						

File: PGPB

PGPUB-DOCUMENT-NUMBER: 20040009501

PGPUB-FILING-TYPE: new

L7: Entry 30 of 44

DOCUMENT-IDENTIFIER: US 20040009501 A1

TITLE: Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937,

49931 and 49933 molecules and uses therefor


PUBLICATION-DATE: January 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Curtis, Rory A. J.	Ashland	MA	US
Logan, Thomas Joseph	Springfield	PA	US
Glucksmann, Maria Alexandra	Lexington	MA	US
Meyers, Rachel E.	Newton	MA	US
Williamson, Mark J.	Saugus	MA	US

Rudolph-Owen, Laura A.	Medford	MA	US
Chun, Miyoung	Belmont	MA	US
Tsai, Fong-Ying	Newton	MA	US

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2



Display Format: - Change Format

Previous Page Next Page Go to Doc#

## Hit List

First Hit Clear: Generate Collection Print Fwd Refs Bkwd Refs Generate OACS

Search Results - Record(s) 31 through 44 of 44 returned.

☐ 31. Document ID: US 20040005664 A1

Using default format because multiple data bases are involved.

L7: Entry 31 of 44

File: PGPB

Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040005664

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040005664 A1

TITLE: Novel 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565,

13305, 14911, 86216, 25206 and 8843 molecules and uses therefor

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Meyers, Rachel E.	Newton	MA	US
MacBeth, Kyle J.	Boston	MA	US
Curtis, Rory A. J.	Ashland	MA	US
Rudolph-Owen, Laura A.	Medford	MA	US
Weich, Nadine S.	Brookline	MA	US
Olandt, Peter J.	Buffalo	NY	US
Tsai, Fong-Ying	Newton	MA	US
Kapeller-Libermann, Rosana	Chestnut Hill	MA	US
Carroll, Joseph M.	Cambridge	MA	US

US-CL-CURRENT:  $\underline{435}/\underline{69.1}$ ;  $\underline{435}/\underline{320.1}$ ,  $\underline{435}/\underline{325}$ ,  $\underline{435}/\underline{6}$ ,  $\underline{530}/\underline{350}$ ,  $\underline{530}/\underline{388.22}$ ,  $\underline{536}/\underline{23.5}$ 

Full Title Citation	Front Review	Classification   Date	:   Reference   Sequences	:  Attachments   Claims	KMC Draw, De

☐ 32. Document ID: US 20030235820 A1

L7: Entry 32 of 44

File: PGPB

Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030235820

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030235820 A1

TITLE: Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

Mack, David H. Menlo Park CA US Markowitz, Sanford David Pepper Pike OH US

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 435/7.23, 530/388.26, 536/23.2

- 1													
	Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC	Draw, De
_													

☐ 33. Document ID: US 20030229455 A1

L7: Entry 33 of 44

File: PGPB

Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229455

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030229455 A1

TITLE: SYSTEMS AND METHODS FOR CHARACTERIZING A BIOLOGICAL CONDITION OR AGENT USING

PRECISION GENE EXPRESSION PROFILES

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY Bevilacqua, Michael P. Boulder CO US Bankaitis-Davis, Danute M. Longmont CO US Cheronis, John C. Conifer CO US Tryon, Victor Loveland CO US

US-CL-CURRENT: 702/20; 435/6

					,							
Full	Title	Citation	Front	Review	Classification	Dista	Potoropoo	Seguences	Attachmanta	Claima	KOMO	Draw, De
	1111	Citation	110111	Liveniene	Classification	Date	Melelence	Sequences	Attacriments	Claims	KOOLC	DIAME DE

☐ 34. Document ID: US 20030224335 A1

L7: Entry 34 of 44

File: PGPB

Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224335

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030224335 A1

TITLE: Receptor linked protein tyrosine phosphatases

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

Frederick, Christin Newton MA US Saito, Haruo Newton MA US US-CL-CURRENT: 434/193; 436/86

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw. De

☐ 35. Document ID: US 20030166224 A1

L7: Entry 35 of 44

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166224

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030166224 A1

TITLE: 18232, a novel dual specificity phosphatase and uses therefor

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

Meyers, Rachel A. Newton MA US Weich, Nadine Brookline MA US

US-CL-CURRENT: 435/196; 435/320.1, 435/325, 435/69.1, 536/23.2

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw. De

☐ 36. Document ID: US 20030166067 A1

L7: Entry 36 of 44 File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166067

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030166067 A1

TITLE: Islet cell antigen 1851

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY Kindsvogel, Wayne Seattle WA US Jelinek, Laura J. Seattle WA US Sheppard, Paul O. Granite Falls WA US Hagopian, William A. Seattle WA US LaGasse, James M. Seattle WΑ US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/326, 435/7.21, 530/350,

530/388.26, 536/23.5

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw. De

☐ 37. Document ID: US 20030158083 A1

L7: Entry 37 of 44

File: PGPB

Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030158083

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030158083 A1

TITLE: Method of effecting angiogenesis by modulating the function of a novel

endothelia phosphatase

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME CITY

STATE

COUNTRY

Peters, Kevin Gene

Loveland

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draws De

OH

US

 $\text{US-CL-CURRENT: } \underline{514/1}; \ \underline{424/94.6}, \ \underline{435/196}, \ \underline{435/320.1}, \ \underline{435/325}, \ \underline{435/7.23}, \ \underline{536/23.2}$ 

☐ 38. Document ID: US 20030054387 A1

L7: Entry 38 of 44

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054387

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030054387 A1

TITLE: Metastasis-associated genes

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Chen, Jeremy J.W.	Fengyuan City		TW
Yang, Pan-Chyr	Taipei		TW
Peck, Konan	Taipei		TW
Hong, Tse-Ming	Taipei		TW
Yang, Shuenn-Chen	Taipei		TW
Wu, Cheng-Wen	Taipei		TW

US-CL-CURRENT: 435/6; 702/20

Full Title Ci	tation Front Revie	w Classification D	ate Reference	Sequences	Attachments	Claims KWIC	Draw. De

☐ 39. Document ID: US 20030027819 A1

L7: Entry 39 of 44

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027819

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030027819 A1

TITLE: Beta-sheet mimetics and methods relating to the use thereof

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Qabar, Maher N.	Redmond	WA	US
McMillan, Michael K.	Bellevue	WA	US
Kahn, Michael S.	Kirkland	WA	US
Tulinsky, John E.	Seattle	WA	US
Ogbu, Cyprian O.	Bellevue	WA	US
Mathew, Jessymol	Bellevue	WA	US

US-CL-CURRENT: <u>514/224.2</u>; <u>514/229.5</u>, <u>514/299</u>, <u>514/367</u>, <u>514/373</u>, <u>514/412</u>, <u>514/434</u>, <u>514/456</u>, <u>514/469</u>

Full Title	Citation   Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWAC	Drawt De
<b>–</b> 40	_									
I 40.	Document I	D: US 2	2002015094	7 <b>A</b> 1						
L7: Entry	40 of 44				File: P	GPB		Oct	17,	2002

PGPUB-DOCUMENT-NUMBER: 20020150947

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020150947 A1

TITLE: Extended tethering approach for rapid identification of ligands

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

L7: Entry 41 of 44

NAME		CITY	STATE	COUNTRY
Erlanson,	Daniel A.	San Francisco	CA	US
Braisted,	Andrew C.	San Francisco	CA	US
McDowell,	Robert	San Francisco	CA	US
Prescott,	John	San Francisco	CA	US

US-CL-CURRENT: 435/7.1; 435/6, 436/518

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw.
					_					·		

File: PGPB

Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146370

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020146370 A1

TITLE: USE OF PROTEIN TYROSINE PHOSPHATASE ZETA AS A BIOMOLECULAR TARGET IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

CITY NAME Mueller, Sabine San Francisco Melcher, Thorsten San Francisco

Chin, Daniel J.

Foster City

CA US

STATE

CA

CA

US-CL-CURRENT: 424/1.69

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMAC	Drawi De
	_							•	•			

☐ 42. Document ID: US 20020102616 A1

L7: Entry 42 of 44

File: PGPB

Aug 1, 2002

COUNTRY

US

US

PGPUB-DOCUMENT-NUMBER: 20020102616

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020102616 A1

TITLE: Islet cell antigen 1851

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY Kindsvogel, Wayne Seattle WA US Jelinek, Laura J. Seattle WA US Sheppard, Paul O. Redmond WA US Hagopian, William A. Seattle WA US LaGasse, James M. Seattle WA US

US-CL-CURRENT:  $\underline{435}/\underline{7.9}$ ;  $\underline{435}/\underline{320.1}$ ,  $\underline{435}/\underline{326}$ ,  $\underline{435}/\underline{69.1}$ ,  $\underline{530}/\underline{387.2}$ ,  $\underline{536}/\underline{23.53}$ 

Full Ti	itle Cita	tion Fro	nt Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC Drat	o.De

☐ 43. Document ID: US 20020065406 A1

L7: Entry 43 of 44

File: PGPB

May 30, 2002

PGPUB-DOCUMENT-NUMBER: 20020065406

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020065406 A1

TITLE: 18221, a novel dual specificity phosphatase and uses thereof

PUBLICATION-DATE: May 30, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

Meyers, Rachel A.

Newton

MA

US

US-CL-CURRENT: 536/23.1; 435/196, 435/6



☐ 44. Document ID: US 20020034807 A1

L7: Entry 44 of 44

File: PGPB

Mar 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020034807

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020034807 A1

TITLE: 38692 and 21117, novel dual specificity phosphatase molecules and uses

therefor

PUBLICATION-DATE: March 21, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

Meyers, Rachel A.


Newton

MA

US

US-CL-CURRENT: 435/196; 435/325, 435/6, 435/69.1, 435/7.1, 514/44, 530/388.1,

536/23.2



Display Format: - Change Format

Previous Page Next Page Go to Doc#

STN SEARCH 10634,027

CORPORATE SOURCE:

SOURCE:

FILE 'HOME' ENTERED AT 17:05:47 ON 07 APR 2006 => s hptpß 15 FILE MEDLINE L15 L16 19 FILE CAPLUS 21 FILE SCISEARCH T.17 10 FILE LIFESCI L18 13 FILE BIOSIS L19 12 FILE EMBASE L20 TOTAL FOR ALL FILES 90 НРТРВ L21 => s 121 and inhibitor 1 FILE MEDLINE L22 L23 3 FILE CAPLUS L24 5 FILE SCISEARCH O FILE LIFESCI L25 1 FILE BIOSIS L26 L27 2 FILE EMBASE TOTAL FOR ALL FILES L28 12 L21 AND INHIBITOR => dup rem 128 PROCESSING COMPLETED FOR L28 8 DUP REM L28 (4 DUPLICATES REMOVED) => d 1-8 ibib abs L29 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN ACCESSION NUMBER: 2004:331682 CAPLUS Full-text DOCUMENT NUMBER: 140:352651 TITLE: The three-dimensional structure of protein tyrosine phosphatase  $\beta$  subunit and its use in drug design INVENTOR(S): Evdokimov, Artem Gennady; Pokross, Matthew Eugene PATENT ASSIGNEE(S): The Procter & Gamble Company, USA SOURCE: U.S. Pat. Appl. Publ., 335 pp. CODEN: USXXCO DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE --<del>-</del>------------US 2003-634027 US 2004077065 20040422 20030804 P 20020925 PRIORITY APPLN. INFO.: US 2002-413547P The crystal structures of the catalytic domain of the human protein tyrosine phosphatase HPTPβ, in ligand-bound and ligand-free forms are described. These structures are useful in computer aided drug design for identifying compds. that bind or activate HPTPbeta and thereby modulate angiogenesis mediated disorders or diseases. L29 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN ACCESSION NUMBER: 2003:580622 CAPLUS Full-text DOCUMENT NUMBER: TITLE: Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component AUTHOR (S): Peters, Kevin G.; Davis, Mike G.; Howard, Brian W.; Pokross, Matthew; Rastogi, Vinit; Diven, Conrad; Greis, Kenneth D.; Eby-Wilkens, Elaine; Maier, Matthew; Evdokimov, Artem; Soper, Shari; Genbauffe, Frank

Cardiovascular Research, Procter & Gamble

OH, 45040, USA

Pharmaceuticals, Health Care Research Center, Mason,

Journal of Inorganic Biochemistry (2003), 96(2-3),

321-330

CODEN: JIBIDJ; ISSN: 0162-0134

Elsevier Science Inc. PUBLISHER:

DOCUMENT TYPE: Journal English LANGUAGE:

Organovanadium compds. have been shown to be insulin sensitizers in vitro and in vivo. One potential biochem, mechanism for insulin sensitization by these compds, is that they inhibit protein tyrosine phosphatases (PTPs) that neg. regulate insulin receptor activation and signaling. In this study, bismaltolato oxovanadium (BMOV), a potent insulin sensitizer, was shown to be a reversible, competitive phosphatase inhibitor that inhibited phosphatase activity in cultured cells and enhanced insulin receptor activation in vivo. NMR and x-ray crystallog. studies of the interaction of BMOV with two different phosphatases, HCPTPA (human low mol. weight cytoplasmic protein tyrosine phosphatase) and PTP1B (protein tyrosine phosphatase 1B), demonstrated uncomplexed vanadium (VO4) in the active site. Taken together, these findings support phosphatase inhibition as a mechanism for insulin sensitization by BMOV and other organovanadium compds. and strongly suggest that uncomplexed vanadium is the active component of these compds.

REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 3 OF 8 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on

ACCESSION NUMBER: 2001:452808 SCISEARCH Full-text

THE GENUINE ARTICLE: 434XQ

TITLE: Potent reversible inhibitors of the protein

tyrosine phosphatase CD45

AUTHOR: Urbanek R A (Reprint); Suchard S J; Steelman G B;

Knappenberger K S; Sygowski L A; Veale C A; Chapdelaine M

CORPORATE SOURCE: AstraZeneca Pharmaceut, 1800 Concord Pike, Wilmington, DE

19850 USA (Reprint); AstraZeneca Pharmaceut, Wilmington,

DE 19850 USA

COUNTRY OF AUTHOR: USA

JOURNAL OF MEDICINAL CHEMISTRY, (24 MAY 2001) Vol. 44, No. SOURCE +

> 11, pp. 1777-1793. ISSN: 0022-2623.

AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036 PUBLISHER:

USA.

DOCUMENT TYPE: LANGUAGE:

Article; Journal

REFERENCE COUNT:

AB

English

66

ENTRY DATE: Entered STN: 15 Jun 2001

Last Updated on STN: 15 Jun 2001

*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

The cytosolic portion of CD45, a major transmembrane glycoprotein found on nucleated hematopoietic cells, contains protein tyrosine phosphatase activity and is critical for T-cell receptor-mediated T-cell activation. CD45 inhibitors could have utility in the treatment of autoimmune disorders and organ graft rejection. A number of 9, 10-phenanthrenediones were identified that reversibly inhibited CD45mediated p-nitrophenyl phosphate (pNPP) hydrolysis. Chemistry efforts around the 9,10-phenanthrenedione core led to the most potent inhibitors known to date. In a functional assay, the compounds were also potent inhibitors of T-cell receptormediated proliferation, with activities in the low micromolar range paralleling their enzyme inhibition. It was also discovered that the nature of modification to the phenanthrenedione pharmacophore could affect selectivity for CD45 over PTP1B (protein tyrosine phosphatase 1B) or vice versa.

L29 ANSWER 4 OF 8 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on

STN

ACCESSION NUMBER: 2000:810169 SCISEARCH Full-text

THE GENUINE ARTICLE: 368FO

TITLE: Enzyme inhibition assays using fluorescence correlation

spectroscopy: A new algorithm for the derivation of k(cat)/K-M and K-i values at substrate concentrations much

lower than the Michaelis constant

AUTHOR: Meyer-Almes F J (Reprint); Auer M

CORPORATE SOURCE: EVOTEC Analyt Syst GmbH, Max Planck Str 15A, D-40699

Erkrath, Germany (Reprint); EVOTEC Analyt Syst GmbH, D-40699 Erkrath, Germany; Novartis Forschungsinst, A-1235

Vienna, Austria

COUNTRY OF AUTHOR: Germany; Austria

SOURCE: BIOCHEMISTRY, (31 OCT 2000) Vol. 39, No. 43, pp.

13261-13268.

ISSN: 0006-2960.

PUBLISHER: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036

USA.

DOCUMENT TYPE: Article; Journal

LANCHAGE. English REFERENCE COUNT: 26

Entered STN: 2000 ENTRY DATE:

Last Updated on STN: 2000

*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

AB A new mathematical formalism is deduced which allows for the calculation of the k(cat) over K-M ratio based on measurements of the enzyme kinetics with substrate concentrations much lower than K-M. The equations are also applied on the action of an inhibitor on enzyme activity yielding the binding constant, K-i, of an inhibitor molecule. For practical evaluation of the new theoretical approach, the enzymatic reaction of CD45 phosphatase was used as a well-characterized model system with known inhibitors for testing the K-i value determination scheme. The

> k(cat)/K-M ratio was calulated to be 4.7 x 10(5) M-1 s(-1), the K-i of the inhibitor molecule PKF52-524 was estimated to be  $(1-2) \times 10(-7) \, \, M$  and the

association rate of the inhibitor PKF52-524 to CD45 phosphatase was estimated to be

59 M-1 s(-1).

L29 ANSWER 5 OF 8 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on

STN

ACCESSION NUMBER: 1999:88596 SCISEARCH Full-text

THE GENUINE ARTICLE: 160TX

TITLE: [Difluro(phosphono)methyl]phenylalanine-containing peptide

inhibitors of protein tyrosine phosphatases

**AUTHOR:** Desmarais S; Friesen R W; Zamboni R; Ramachandran C

(Reprint)

CORPORATE SOURCE: Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res,

Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada (Reprint); Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Dept Med Chem, Pointe Claire, PQ

H9R 4P8, Canada

COUNTRY OF AUTHOR: Canada

SOURCE: BIOCHEMICAL JOURNAL, (15 JAN 1999) Vol. 337, Part 2, pp.

219-223.

ISSN: 0264-6021.

PUBLISHER: PORTLAND PRESS, 59 PORTLAND PLACE, LONDON W1N 3AJ, ENGLAND

DOCUMENT TYPE: Article; Journal

LANGUAGE: English REFERENCE COUNT: 40

ENTRY DATE: Entered STN: 1999

Last Updated on STN: 1999

*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

AB Peptides containing the non-hydrolysable phosphotyrosine analogue 4-

[difluro(phosphono)methyl]phenylalanine [Phe(CF2P)] were synthesized and tested as inhibitors of the protein tyrosine phosphatases (PTPs) PTP1B, CD45, PTP beta, LAR and SHP-1. identified peptides containing two adjacent Phe(CF2P) residues as potent inhibitors of PTPs. The tripeptide having the sequence Glu-Phe(CF2P)-Phe(CF2P) is a potent and selective inhibitor of PTP 1B. This peptide inhibits PTP1B with an IC50 of 40 nM, which is at least 100-fold lower than with other PTPs. A second tripeptide, Pro-Phe(CF2P)-Phe(CF2P), is most potent against PTP beta, with an IC50 of 200 nM, and inhibits PTP1B with an IC50 of 300 nM. These data suggest that it is possible to develop selective, active-site-directed, reversible, potent inhibitors

of PTPs.

L29 ANSWER 6 OF 8 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on

STN

ACCESSION NUMBER: 1998:495221 SCISEARCH Full-text

THE GENUINE ARTICLE: ZW771

Inhibition of protein tyrosine phosphatases PTP1B and CD45

by sulfotyrosyl peptides

AUTHOR: Desmarais S; Jia Z C; Ramachandran C (Reprint)

CORPORATE SOURCE: Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res,
Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R

4P8, Canada (Reprint); Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Queens Univ, Dept Biochem,

Kingston, ON K7L 3N6, Canada

COUNTRY OF AUTHOR: Canada

SOURCE: ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, (15 JUN 1998)

Vol. 354, No. 2, pp. 225-231.

ISSN: 0003-9861.

PUBLISHER: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA

92101-4495 USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 27

ΑB

ENTRY DATE: Entered STN: 1998

Last Updated on STN: 1998

*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

Sulfotyrosyl peptides corresponding to the known high-affinity substrate phosphotyrosyl peptide sequences in casein and the autophosphorylation sites of insulin receptor and EGF receptor were investigated as inhibitors of protein tyrosine phosphatases PTP1B and CD45. These peptides inhibit both PTP1B and CD45 in the micromolar range competitively and reversibly. The elements required for inhibition were investigated by truncation and substitution of these peptides. Acidic residues N-terminal to the sulfotyrosyl residues are essential for high-affinity binding to PTP1B. The recognition elements required for inhibition of PTP1B and CD45 are different and this suggests the possibility of identifying selective active-site-directed inhibitors for these enzymes. (C) 1998 Academic

Press.

L29 ANSWER 7 OF 8 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights

reserved on STN

ACCESSION NUMBER: 94082074 EMBASE <u>Full-text</u>

DOCUMENT NUMBER: 1994082074

TITLE: Characterization and kinetic analysis of the intracellular

domain of human protein tyrosine phosphatase  $\boldsymbol{\beta}$  (

HPTPβ) using synthetic

phosphopeptides.

AUTHOR: Harder K.W.; Owen P.; Wong L.K.H.; Aebersold R.;

Clark-Lewis I.; Jirik F.R.

CORPORATE SOURCE: Biomedicai Research Centre, University of British Columbia,

2222 Health Sciences Mall, Vancouver, BC V6T 123, Canada

SOURCE: Biochemical Journal, (1994) Vol. 298, No. 2, pp. 395-401. .

ISSN: 0264-6021 CODEN: BIJOAK

COUNTRY: United Kingdom DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 029 Clinical Biochemistry

LANGUAGE: English SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 30 Mar 1994

Last Updated on STN: 30 Mar 1994

The intracellular domain of human protein tyrosine phosphatase  $\beta$  (HPTP $\beta$ ) (44 kDa) was expressed in bacteria, purified using epitope 'tagging' immunoaffinity chromatography, and characterized with respect to kinetic profile, substrate specificity and potential modulators of enzyme activity. A chromogenic assay based on the Malachite Green method was employed for the detection of inorganic phosphate (P(i)) released from phosphopeptides by  $\mbox{HPTP}\beta.$  This assay, modified so as to improve its sensitivity, was adapted to a 96-well microtitre plate format, and provided linear detection between 50 and 1000 pmol of P(i). The cytoplasmic domain of HPTPB was strongly inhibited by vanadate, molybdate, heparin, poly(Glu, Tyr) (4:1) and zinc ions. In order to explore the substrate preferences of this PTPase, we generated 13-residue synthetic phosphotyrosine-containing peptides that corresponded to sites of physiological tyrosine phosphorylation. HPTPB demonstrated k(cat.) values between 76 and 258 s-1 using four different phosphopeptides. The substrate preference of HPTPβ was in the order src(Tyr-527) > PDGF-R(Tyr-740) > ERK1(Tyr-204) >> CSF-1R(Tyr-708) with K(m) values ranging from 140  $\mu M$  to greater than 10 mM. The variations in affinity were probably due to differences among the four phosphopeptides compared, particularly with respect to the character of the charged amino acids flanking the phosphotyrosine residue.

L29 ANSWER 8 OF 8 MEDLINE on STN DUPLICATE 1

ACCESSION NUMBER: 93306206 MEDLINE Full-text

DOCUMENT NUMBER: PubMed ID: 8318901

TITLE: Substrate specificities of catalytic fragments of protein

tyrosine phosphatases (HPTP beta, LAR,

and CD45) toward phosphotyrosylpeptide substrates and

thiophosphotyrosylated peptides as inhibitors.

AUTHOR: Cho H; Krishnaraj R; Itoh M; Kitas E; Bannwarth W; Saito H;

Walsh C T

CORPORATE SOURCE: Department of Biological Chemistry and Molecular

Pharmacology, Harvard Medical School, Boston, Massachusetts

02115.

SOURCE: Protein science : a publication of the Protein Society,

(1993 Jun) Vol. 2, No. 6, pp. 977-84. Journal code: 9211750. ISSN: 0961-8368.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199308

ENTRY DATE: Entered STN: 19930813

Last Updated on STN: 19970203 Entered Medline: 19930805

AB The transmembrane PTPase HPTP beta differs from its related family members in having a single rather than a tandemly duplicated cytosolic catalytic domain. We have expressed the 354-amino acid, 41-kDa human PTP beta catalytic fragment in Escherichia coli, purified it, and assessed catalytic specificity with a series of pY peptides. HPTP beta shows distinctions from the related LAR PTPase and T cell CD45 PTPase domains: it recognizes phosphotyrosyl peptides of 9-11 residues from lck, src, and PLC gamma with Km values of 2, 4, and 1 microM, some 40-200-fold lower than the other two PTPases. With kcat values of 30-205 s-1, the catalytic efficiency, kcat/Km, of the HPTP beta 41-kDa catalytic domain is very high, up to 5.7 x 10(7) M-1 s-1. The peptides corresponding to PLC gamma (766-776) and EGFR (1,167-1,177) phosphorylation sites were used for structural variation to assess pY sequence context recognition by HPTP beta catalytic domain. While exchange of the alanine residue at the +2 position of the PLC gamma (Km of 1 microM) peptide to lysine or aspartic acid showed little or no effect on substrate affinity, replacement by arginine increased the Km 35-fold. Similarly, the high Km value of the EGFR pY peptide (Km of 104 microM) derives largely from the arginine residue at the +2 position of the peptide, since arginine to alanine single mutation at the -2 position of the EGFR peptide decreased the Km value 34-fold to 3 microM. Three thiophosphotyrosyl peptides have been prepared and act as substrates and competitive inhibitors of these PTPase catalytic domains.

TOTAL FOR ALL FILES

L36 4 L21 AND (X-RAY OR CRYSTAL)

=> dup rem 136

INVENTOR(S):

PROCESSING COMPLETED FOR L36

L37 4 DUP REM L36 (0 DUPLICATES REMOVED)

=> d ibib abs 1-4

L37 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN ACCESSION NUMBER: 2004:331682 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 140:352651

TITLE: The three-dimensional structure of protein tyrosine

phosphatase  $\beta$  subunit and its use in drug design Evdokimov, Artem Gennady; Pokross, Matthew Eugene

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA SOURCE: U.S. Pat. Appl. Publ., 335 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ---------______ US 2003-634027 US 2004077065 A1 20040422 20030804 P 20020925 PRIORITY APPLN. INFO.: US 2002-413547P

The crystal structures of the catalytic domain of the human protein tyrosine phosphatase HPTPβ, in ligand-bound and ligand-free forms are described. These structures are useful in computer aided drug design for identifying compds. that bind or activate HPTPbeta and thereby modulate angiogenesis mediated disorders or diseases.

L37 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN 2003:580622 CAPLUS Full-text

ACCESSION NUMBER:

DOCUMENT NUMBER: 140:87438

TITLE: Mechanism of insulin sensitization by BMOV (bis

maltolato oxo vanadium); unliganded vanadium (VO4) as

the active component

AUTHOR (S): Peters, Kevin G.; Davis, Mike G.; Howard, Brian W.;

Pokross, Matthew; Rastogi, Vinit; Diven, Conrad; Greis, Kenneth D.; Eby-Wilkens, Elaine; Maier, Matthew; Evdokimov, Artem; Soper, Shari; Genbauffe,

Frank

CORPORATE SOURCE: Cardiovascular Research, Procter & Gamble

Pharmaceuticals, Health Care Research Center, Mason,

OH, 45040, USA

SOURCE: Journal of Inorganic Biochemistry (2003), 96(2-3),

321-330

CODEN: JIBIDJ; ISSN: 0162-0134

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal LANGUAGE: English

Organovanadium compds. have been shown to be insulin sensitizers in vitro and in vivo. AB One potential biochem. mechanism for insulin sensitization by these compds. is that they inhibit protein tyrosine phosphatases (PTPs) that neg. regulate insulin receptor activation and signaling. In this study, bismaltolato oxovanadium (BMOV), a potent insulin sensitizer, was shown to be a reversible, competitive phosphatase inhibitor that inhibited phosphatase activity in cultured cells and enhanced insulin receptor activation in vivo. NMR and x-ray crystallog. studies of the interaction of BMOV with two different phosphatases, HCPTPA (human low mol. weight cytoplasmic protein tyrosine phosphatase) and PTP1B (protein tyrosine phosphatase 1B), demonstrated uncomplexed vanadium (VO4) in the active site. Taken together, these findings support phosphatase inhibition as a mechanism for insulin sensitization by BMOV and other organovanadium compds. and strongly suggest

that uncomplexed vanadium is the active component of these compds.

REFERENCE COUNT: THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS 70 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 3 OF 4 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on

STN

ACCESSION NUMBER: 1998:495221 SCISEARCH Full-text

THE GENUINE ARTICLE: ZW771

TITLE: Inhibition of protein tyrosine phosphatases PTP1B and CD45

by sulfotyrosyl peptides

AUTHOR: Desmarais S; Jia Z C; Ramachandran C (Reprint)

CORPORATE SOURCE:

Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada (Reprint); Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Queens Univ, Dept Biochem,

Kingston, ON K7L 3N6, Canada

COUNTRY OF AUTHOR: Canada

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, (15 JUN 1998) SOURCE:

Vol. 354, No. 2, pp. 225-231.

ISSN: 0003-9861.

PUBLISHER: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA

92101-4495 USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English REFERENCE COUNT: 27

ENTRY DATE: Entered STN: 1998

Last Updated on STN: 1998

*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

AB

Sulfotyrosyl peptides corresponding to the known high-affinity substrate phosphotyrosyl peptide sequences in casein and the autophosphorylation sites of insulin receptor and EGF receptor were investigated as inhibitors of protein tyrosine phosphatases PTP1B and CD45. These peptides inhibit both PTP1B and CD45 in the micromolar range competitively and reversibly. The elements required for inhibition were investigated by truncation and substitution of these peptides. Acidic residues N-terminal to the sulfotyrosyl residues are essential for highaffinity binding to PTP1B. The recognition elements required for inhibition of PTP1B and CD45 are different and this suggests the possibility of identifying selective active-site-directed inhibitors for these enzymes. (C) 1998 Academic Press.

L37 ANSWER 4 OF 4 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on

STN

ACCESSION NUMBER: 1998:125157 SCISEARCH Full-text

THE GENUINE ARTICLE: YW343

TITLE: Sequence-specific recognition of peptide substrates by the low M-r phosphotyrosine protein phosphatase isoforms

AUTHOR: Bucciantini M; Stefani M (Reprint); Taddei N; Chiti F;

Rigacci S; Ramponi G

CORPORATE SOURCE: Univ Florence, Dept Biochem Sci, Viale Morgagni 50,

I-50134 Florence, Italy (Reprint); Univ Florence, Dept

Biochem Sci, I-50134 Florence, Italy

COUNTRY OF AUTHOR: Italy

SOURCE: FEBS LETTERS, (30 JAN 1998) Vol. 422, No. 2, pp. 213-217.

TSSN: 0014-5793.

PUBLISHER: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM,

NETHERLANDS.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 32

AR

ENTRY DATE: Entered STN: 1998

Last Updated on STN: 1998

*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

A number of phosphotyrosine-containing peptides derived from the PDGF receptor phosphorylation sites have been synthesised. The peptides were assayed as substrates of the two isoforms (IF1 and IF2) of the low M-r PTPase. The calculated k(cat), K-m, and k(cat)/K-m values indicate that only one peptide is best hydrolysed by IF2 (but not IF1), whose catalytic efficiency averages those previously reported for most PTPases (except the Yersinia enzyme). This peptide is the only one containing a couple of no bulky hydrophobic residues at the phosphotyrosine N-side. The determination of the same catalytic parameters in the presence of analogues of the best hydrolysed peptide in which one or both hydrophobic residues were replaced by Asp or Lys residues confirmed the importance

of the hydrophobic cluster at the phosphotyrosine N-side for optimal enzymatic hydrolysis. These findings are discussed in the light of the known IF2 X-ray structure. (C) 1998 Federation of European Biochemical Societies.

=> s human protein tyrosine phosphataseβ

2 FILE MEDLINE L38 1.39 2 FILE CAPLUS L40 2 FILE SCISEARCH L410 FILE LIFESCI L42 2 FILE BIOSIS 2 FILE EMBASE L43

TOTAL FOR ALL FILES

10 HUMAN PROTEIN TYROSINE PHOSPHATASEB

=> dup rem 144

PROCESSING COMPLETED FOR L44

2 DUP REM L44 (8 DUPLICATES REMOVED) L45

=> d ibib abs 1-2

L45 ANSWER 1 OF 2 MEDLINE on STN DUPLICATE 1

ACCESSION NUMBER: 95291173 MEDLINE Full-text

DOCUMENT NUMBER: PubMed ID: 7539661

TITLE: High-sensitivity determination of tyrosine-phosphorylated

peptides by on-line enzyme reactor and electrospray

ionization mass spectrometry.

AUTHOR: Amankwa L N; Harder K; Jirik F; Aebersold R

CORPORATE SOURCE: Biomedical Research Centre, University of British Columbia,

Vancouver, Canada.

SOURCE: Protein science : a publication of the Protein Society,

(1995 Jan) Vol. 4, No. 1, pp. 113-25. Journal code: 9211750. ISSN: 0961-8368.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199507

ENTRY DATE: Entered STN: 19950720

Last Updated on STN: 19960129

Entered Medline: 19950713

AB We describe a simple, fast, sensitive, and nonisotopic bioanalytical technique for the detection of tyrosine-phosphorylated peptides and the determination of sites of protein

detection of tyrosine-phosphorylated peptides and the determination of sites of proteir tyrosine phosphorylation. The technique employs a protein tyrosine phosphatase micro enzyme reactor coupled on-line to either capillary electrophoresis or liquid

chromatography and electrospray ionization mass spectrometry instruments. The micro enzyme reactor was constructed by immobilizing genetically engineered, metabolically biotinylated human protein tyrosine phosphatase beta onto the inner surface of a small piece of a 50-microns inner diameter, 360-microns outer diameter fused silica capillary or by immobilization of the phosphatase onto 40-90-microns avidin-activated resins. By coupling these reactors directly to either a capillary electrophoresis column or a liquid chromatography column, we were able to rapidly perform enzymatic dephosphorylation and separation of the reaction products. Detection and identification of the components of the reaction mixture exiting these reactors were done by mass analysis with an on-line electrospray ionization mass spectrometer. Tyrosine-phosphorylated peptides, even if present in a complex peptide mixture, were identified by subtractive analysis of peptide patterns generated with or without phosphatase treatment. Two criteria, namely a phosphatase-induced change in hydropathy and charge, respectively, and a change in molecular mass by 80 Da, were used jointly to identify phosphopeptides. We demonstrate that, with this technique, low picomole amounts of a tyrosine-phosphorylated peptide can be detected in a complex peptide mixture generated by proteolysis of a protein and that

even higher sensitivities can be realized if more sensitive detection systems are applied.

L45 ANSWER 2 OF 2 MEDLINE on STN DUPLICATE 2

ACCESSION NUMBER: 94183168 MEDLINE Full-text

DOCUMENT NUMBER: PubMed ID: 8135747

TITLE: Characterization and kinetic analysis of the intracellular

domain of human protein

tyrosine phosphatase beta (HPTP beta) using synthetic phosphopeptides.

AUTHOR: Harder K W; Owen P; Wong L K; Aebersold R; Clark-Lewis I;

Jirik F R

CORPORATE SOURCE: Biomedical Research Centre, University of British Columbia,

Vancouver, Canada.

SOURCE: The Biochemical journal, (1994 Mar 1) Vol. 298 ( Pt 2), pp.

395-401.

Journal code: 2984726R. ISSN: 0264-6021.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199404

ENTRY DATE: Entered STN: 19940428

Last Updated on STN: 19970203 Entered Medline: 19940415

AB The intracellular domain of human protein tyrosine phosphatase beta (HPTP beta) (44 kDa) was expressed in bacteria, purified using epitope 'tagging' immunoaffinity chromatography, and characterized with respect to kinetic profile, substrate specificity and potential modulators of enzyme activity. A chromogenic assay based on the Malachite Green method was employed for the detection of inorganic phosphate (Pi) released from phosphopeptides

by HPTP beta. This assay, modified so as to improve its sensitivity, was adapted to a 96-well microtitre plate format, and provided linear detection between 50 and 1000 pmol of Pi. The cytoplasmic domain of HPTP beta was strongly inhibited by vanadate, molybdate, heparin, poly(Glu, Tyr) (4:1) and zinc ions. In order to explore the substrate preferences of this PTPase, we generated 13-residue synthetic phosphotyrosine- containing peptides that corresponded to sites of physiological tyrosine phosphorylation. HPTP beta demonstrated kcat. values between 76 and 258 s-1 using four different phosphopeptides. The substrate preference of HPTP beta was in the order srcTyr-527 > PDGF-RTyr-740 > ERKITyr-204 >> CSF-1RTyr-708 with Km values ranging from 140 microM to greater than 10 mM. The variations in affinity were probably due to differences among the four phosphopeptides compared, particularly with respect to the character of the charged amino acids flanking the phosphotyrosine residue.

=> log y